The journal of allergy and clinical immunology. In practice · 2026
Pollen Food Allergy Syndrome-Two Decades Apart: A Follow-up AAAAI Survey.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wong Lydia Su Yin, Cox Amanda, Cianferoni Antonella, Katelaris Constance, Ebo Didier G, Konstantinou George N, Brucker Hannelore, Protudjer Jennifer L P, Hsu Blatman Karen S, Boechat José Laerte, Yu Joyce E, Wang Julie, Blazowski Lukasz, Anand Mahesh Padukudru, Torres Maria J, Holbreich Mark, Wasserman Richard L, Sato Sakura, Al-Shaikhly Taha, Yang Hyeon-Jong, Skypala Isabel J, Nowak-Wegrzyn Anna
Аннотация
BACKGROUND: Pollen food allergy syndrome (PFAS), also called oral allergy syndrome, results from cross-reactivity between pollen allergens and plant-derived foods. Although typically mild, PFAS can occasionally cause systemic reactions. A 2003 US survey characterized its epidemiology and management; this study repeated the survey in 2023 to assess changes.
OBJECTIVE: To evaluate changes in prevalence, clinical patterns, diagnostic practices, and management of PFAS among US allergists over 2 decades.
METHODS: A 16-question survey (7 original and 9 new) was electronically distributed to 737 randomly selected American Academy of Allergy, Asthma & Immunology members in October 2023, and results were compared with 2003 survey responses.
RESULTS: Sixty-seven allergists (9%) responded. The reported prevalence of PFAS increased in children (median 5%-10%, P = .01) and adults (8%-20%, P < .001). The proportion of allergists with patients experiencing systemic PFAS rose from 20% to 67%, though the median percentage of affected patients declined (5%-1%). Grass pollen emerged as a key sensitizer, alongside birch and ragweed. Nut-induced PFAS was increasingly recognized, cited as a frequent trigger of systemic symptoms and a reason for epinephrine autoinjector (EAI) prescription. Overall, EAI prescribing declined, with 0% of allergists "always" prescribing in 2023 versus 30% in 2003. Diagnostic practices showed increased but limited use of component-resolved diagnostics, whereas dietary advice remained variable, especially for nut PFAS.
CONCLUSION: Allergists report a higher estimated prevalence of PFAS, greater recognition of nut-induced and systemic PFAS, and evolving diagnostic and management practices. Findings underscore the need for updated guidelines on PFAS diagnosis and management.
OBJECTIVE: To evaluate changes in prevalence, clinical patterns, diagnostic practices, and management of PFAS among US allergists over 2 decades.
METHODS: A 16-question survey (7 original and 9 new) was electronically distributed to 737 randomly selected American Academy of Allergy, Asthma & Immunology members in October 2023, and results were compared with 2003 survey responses.
RESULTS: Sixty-seven allergists (9%) responded. The reported prevalence of PFAS increased in children (median 5%-10%, P = .01) and adults (8%-20%, P < .001). The proportion of allergists with patients experiencing systemic PFAS rose from 20% to 67%, though the median percentage of affected patients declined (5%-1%). Grass pollen emerged as a key sensitizer, alongside birch and ragweed. Nut-induced PFAS was increasingly recognized, cited as a frequent trigger of systemic symptoms and a reason for epinephrine autoinjector (EAI) prescription. Overall, EAI prescribing declined, with 0% of allergists "always" prescribing in 2023 versus 30% in 2003. Diagnostic practices showed increased but limited use of component-resolved diagnostics, whereas dietary advice remained variable, especially for nut PFAS.
CONCLUSION: Allergists report a higher estimated prevalence of PFAS, greater recognition of nut-induced and systemic PFAS, and evolving diagnostic and management practices. Findings underscore the need for updated guidelines on PFAS diagnosis and management.